Astellas Pharma Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company are Dominating the Market for Global Prophylaxis of Organ Rejection Market in 2020

Global Prophylaxis of Organ Rejection Market is expected to grow at a substantial CAGR of 4.4% in the forecast period 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-prophylaxis-of-organ-rejection-market

Global prophylaxis of organ rejection market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased various strategic developments owing to favourable market scenario.

The major players dealing in global prophylaxis of organ rejection market are introducing strong range of product portfolio. This has also helped the company to maximize the sales with enhanced product portfolio.

Astellas Pharma Inc. is the dominating player in the prophylaxis of organ rejection market and accounts the highest market share in 2021, which is followed by F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Novartis AG, Veloxis Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC, PanaceaBiotech Ltd, and Pfizer, Inc. among others.

Prophylaxis of Organ Rejection MarketAstellas Pharma Inc.:

Allergan headquartered in Tokyo, Japan was incorporated in 2005 after the merger of two pharmaceutical companies that are, Yamanouchi and Fujisawa. The company is focused on developing, manufacturing and commercializing of various pharmaceutical, biologic, and regenerative medicine products.  The company is urology, immunology, cardiology, infectious diseases and other categories. The market focus products come under one of the best-selling products list of the company.

  • In July, 2021 PROGRAF become the first immunosuppressive drug approved in the U.S. for people including adults and paediatric receiving lung transplant approved by FDA (Food and Drug Administration). PROGRAF is a prescription medicine used with other corticosteroids and immunosuppressive to prevent organ rejection post organ transplant.

It has its global networks through direct sales representatives and distributors North America, South America, Europe, Asia-Pacific, Middle East and Africa.

F. Hoffmann-La Roche Ltd.:

F. Hoffmann-La Roche Ltd headquartered in Basel, Switzerland was founded in 1896. The company is focused on development of innovative medicines and diagnostics tests that help patients live longer, better lives. The company is providing brands under Oncology, Immunology, Ophthalmology, Infectious Diseases, Cardio metabolism, Neuroscience, Other product categories. The market focus products lie under Immunology category. The company is continuously engaged in manufacturing and developments of prophylaxis of organ rejection products. Many products are under clinical trials which will aid patients post organ transplant. For instance,

  • In October 2021, F. Hoffmann-La Roche Ltd has launched two new clinical studies of obinutuzumab (Trade name: Gazyva/Gazyvaro) for lupus nephritis and membranous nephropathy under its immunology segment, which is currently is in phase 3 and the expected date of filing is 2024.

The company has wide global presence across the globe such as America, Europe, Africa, and Oceania.

Bristol-Myers Squibb Company:

Merz Pharma has headquartered in New York, United States. The company focuses on discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. The company is providing product under haematology, cardiovascular, immunology, fibrotic diseases, neuroscience and other categories. The market focus products lie under others category. The Company engaged in business expansion through strategic agreement and product approvals.

  • In December 2021, U.S. Food and Drug Administration approved Orencia® (abatacept) in combination with a calcineurin inhibitor and methotrexate for the prevention of acute graft versus host disease (aGvHD) in patients undergoing hematopoietic stem cell transplant from a matached or 1 Allele-mismatched unrelated donor.

The company has wide global presence across the globe such as Europe, Asia-Pacific, Middle East, Latin America, and North America.